RE-BVS – Piemonte Repository

Sfoglia per AUTORE
LINTON K
Collezione AOU Città della Salute di Torino

Items : 5

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. in Leukemia / Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13.

2022
AOU Alessandria
AOU Città della Salute di Torino

Deckert M; Ponzoni M; Pennese E; Cabras G; Thurner L; Smith J; Rummel M; Hertenstein B; Schmoll HJ; Krause SW; Zanni M; Pisani F; Orsucci L; Tucci A; Panse J; Stilgenbauer S; Hess G; Keller U; Balzarotti M; Pukrop T; Gørløv JS; Linton KM; Johnson PW; Hemmaway C; Roth A; Krampera M; Ilariucci F; Fabbri A; Binder M; et alii...

MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5.

2021
AOU Città della Salute di Torino
AOU Novara

Liberati AM; Novak U; Osborne W; Frezzato M; Fox CP; Davies A; Cascavilla N; Bernardi M; Gastaldi E; Cozens K; Bromberg JEC; Singh V; Fanni A; Re F; Patti C; McKay P; Olivieri J; Linton K; Nassi L; Cellini C; Botto B; Cattaneo C; Khwaja J; Luppi M; Calimeri T; Doorduijn JK; Re A; Cabras MG; Smith J; et alii...

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2017 Sep 1;28(9):2169-2178. doi: 10.1093/annonc/mdx289.

2017
AOU Città della Salute di Torino

Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL;

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17.

2017
AOU Città della Salute di Torino

Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; et alii...

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.

2016
AOU Città della Salute di Torino

Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; et alii...